Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Sifrol® Tablets
NCT06457204Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Pramipexole in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point at 48 hours and Maximum Measured Concentration of Pramipexole in Plasma at 48 hours. Started Jul 2024; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06457204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06457204.